COVAX + PPV23

**COVAX + PPV23** refers to the **co-administration of CoronaVac (an inactivated SARS-CoV-2 vaccine) and the 23-valent pneumococcal polysaccharide vaccine (PPSV23, marketed as Pneumovax 23)**. - **CoronaVac** induces immunity against SARS-CoV-2 by presenting inactivated whole virus to stimulate an immune response predominantly via neutralizing antibody production and cellular immunity. - **PPV23** provides immunity against 23 serotypes of *Streptococcus pneumoniae* by eliciting a T cell-independent humoral response against capsular polysaccharides, promoting opsonization and phagocytic killing. - Co-administration is designed to facilitate broad immunization coverage, especially in adults at risk for both COVID-19 and pneumococcal disease. - Recent phase 4 trials show that such co-administration is safe, with immunogenicity for each vaccine largely maintained, though there may be small reductions in antibody titers, particularly in younger adults[1]. - Used principally as a public health intervention in adult and elderly populations for prevention of COVID-19 and invasive pneumococcal disease[1][2][5].

Brand names

Pneumovax 23Pneumovax23Pneumovax-23

Other names

CoronaVac + 23-valent pneumococcal polysaccharide vaccineCoronaVac + PPSV23